Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116104 | 0.93 | GRM5 (0.47) | GRM5KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL20116106 | 0.93 | GRM5 (0.47) | GRM5KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL30506241 | 0.93 | GRM5 (0.47) | GRM5KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL20116103 | 0.93 | GRM5 (0.47) | GRM5KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL30506344 | 0.93 | GRM5 (0.47) | GRM5KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL22358101 | 0.91 | MAPT (0.51) | GRM5LMNATP53 | |
| SCHEMBL22357986 | 0.91 | GRM5 (0.42) | GRM5KCNH2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL22357987 | 0.91 | GRM5 (0.42) | GRM5KCNH2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL20116654 | 0.91 | GRM5 (0.42) | GRM5KCNH2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL22357841 | 0.91 | GRM5 (0.40) | GRM5KCNH2CNR2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | GRM5 68/4885KCNH2 1329/4885CNR2 338/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | GRM5 68/4885KCNH2 1329/4885CNR2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.